KCT0001757已完成未知
A randomized, open-label, single dose, 2-way crossover study to compare the pharmacokinetic characteristics of CKD-395 0.25/750 mg in healthy male volunteers
Chong Kun Dang0 个研究点目标入组 26 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- Male
入选标准
- •1.Healthy man older than 19 years at the time of screening.
- •2.BMI more than 17.5kg/m2 and less than 30.5kg/m2 and weight more than 55kg
- •3.Subject without congenital or chronic diseases and no psychotic symptoms or findings from the medical examination.
- •4.Suitable subject who is determined by laboratory tests such as hematology tests,blood chemistry, urinalysis test according to the characteristics of the drug and screening tests such as ECG test.
- •5.Subject who fully understand the clinical trials after in-depth explanation given prior to the clinical study, decided to join the clinical trials by their will and signed consent form which approved by Chonbuk National University Hospital IRB.
- •6.Subjects who are able to comply with all scheduled visits, laboratory tests and other procedures.
排除标准
- •1.Subjects who has a history of blood, kidneys, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurological or allergic diseases that is clinically significant (Except untreated asymptomatic seasonal allergies at the time of administration)
- •2.Subjects who has a history of gastrointestinal disease or gastrointestinal surgery which can affect drug absorption.
- •3.Subjects who show alanine transferase or aspartate aminotransferase > 2 times upper limit of normal range.
- •4.Subjects who drink Alcohol > 210g/week within 6 months prior to the screening.
- •5.Subjects who take the medication involved in other clinical trials or bioequivalence tests within three months before the first dose medication characters.
- •6.Subjects who show Systolic Blood Pressure > 140 mmHg or Diastolic Blood Pressure > 90 mmHg at screening.
- •7.Subjects who have history of alcohol or drug abuse, within 1 year
- •8.Subjects who treated with metabolizing enzyme inducers or inhibitors such as barbitals within 30days prior to the first dosing.
- •9.Smoker ( = 20cigarettes/day)
- •10.Subjects who takes ethical the count or over the count medicine within 10days before the first investigational product administration.
- •11.Subjects who do the whole blood donation within two months or component blood donation within 1month prior to the first dosing.
- •12.Subjects who can increase risk due to clinical test and administration of drugs or has Severe grade / chronic medical, mental condition or abnormal laboratory result that may interfere with the analysis of test results.
- •13.Patients with hypersensitivity to lobeglitazone or any other thiazolidinediones ( Rosiglitazone, Rioglitazone) and to Metformin or any other biguanides
- •14.Patients with severe heart failure or congestive heart failure of needing drug therapy
- •15.Patients with liver disease
- •16.Patients with severe renal disease
- •17.Patients with diabetes mellitus with ketoacidosis, diabetes coma and prior
- •18.Patients before or after surgery, with severe infections, severe trauma
- •19.Subjects with hereditary diseases of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
- •20.Patients with renal disease or renal failure caused by cardiovascular collapse, acute myocardial infarction, sepsis (Serum creatinine = 1.5mg/dL or abnormal creatine clearance)
- •21.Patients who had a test to injecting radioactive iodine in vein
- •22.Patients with severe infections or severe traumatic whole body injuries
- •23.Patients with undernourishment condition or starvation state or hyposthenia or hypopituitarism, or hypoadrenalism
- •24.Patients with respiratory failure, or stomach disease
- •25.Subjects who is not able to intake high fat meals
- •26.Subjects who is not able to comply with guidelines described in the protocol.
- •27.Subjects who is determined by investigator's decision as unsuitable for clinical trial participation.
研究者
相似试验
已完成
不适用
A randomized, open-label, single dose, 2-way crossover study to evaluate the pharmacokinetic characteristics of EL-1401 in comparison to the co-administration of nebivolol and rosuvastatin in healthy volunteersDiseases of the circulatory systemKCT0002283Elyson Pharmaceutical50
已完成
不适用
investigate the effect of food on the pharmacokinetic characteristics of CKD-395KCT0001783Chong Kun Dang16
进行中（未招募）
不适用
A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/750 mg in Healthy Male VolunteersEndocrine, nutritional and metabolic diseaseKCT0001844Chong Kun Dang26
已完成
不适用
A clinical study to compare the pharmacokinetic characteristics of CKD-395 0.5/1000 mg in healthy male volunteersEndocrine, nutritional and metabolic diseaseKCT0001627Chong Kun Dang26
已完成
不适用
A Phase 1 Clinical Trial to Investigate Pharmacokinetics and Bioequivalence of the co-administration of telmisartan and rosuvastatin and YH16410KCT0001231Yuhan180